Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.08. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
12.08. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
26.06. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
28.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
06.05. | OnKure Therapeutics GAAP EPS of $1.19 | 1 | Seeking Alpha | ||
06.05. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
06.05. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 185 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen | |
06.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
30.04. | Evercore ISI starts OnKure stock with Outperform rating | 2 | Investing.com | ||
10.03. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 289 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen | |
10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 272 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 23,400 | +0,04 % | Achtung Übernahmen! BioTechs wie Evotec, PanGenomic Health, Pfizer und BioNTech im Fokus | Die BioTech-Branche ist in Aufruhr! Mit dem Wegfall von Blockbuster-Patenten drohen kräftige Umsatzrückgänge, die strategisch kompensiert werden müssen. Angetrieben durch wirtschaftlichen Druck und... ► Artikel lesen | |
SANOFI | 86,71 | +0,24 % | Steht die Sanofi-Aktie vor einem Comeback? Milliardenpotenzial in der Immunologie! | Sanofi glänzt mit starken Studiendaten und Milliardenpotenzial in der Immunologie. Berenberg sieht die Aktie als klar unterbewertet und hebt das Kursziel auf 110 Euro an. Analysten rechnen mit einer... ► Artikel lesen | |
INNOCAN PHARMA | 10,780 | -3,40 % | InnoCan Pharma: Ist die Nasdaq-Rallye schon gestartet? | ||
ASSEMBLY BIOSCIENCES | 20,000 | +1,01 % | Assembly Biosciences: Mega-Daten und Investoren-Ansturm | Es geht Schlag auf Schlag: Heute Morgen erst hatte ich über die neuesten, positiven Entwicklungen bei Assembly Biosciences berichtet, schon folgen die nächsten Kracher, die für ein neues Kurshoch sorgen.... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 49,600 | -2,75 % | Nektar Therapeutics: Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 | SAN FRANCISCO, Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase... ► Artikel lesen | |
JAGUAR HEALTH | 2,215 | +0,23 % | Jaguar Health, Inc.: FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease | The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar... ► Artikel lesen | |
UNITED THERAPEUTICS | 383,30 | -0,39 % | TD Cowen bestätigt Kaufempfehlung für United Therapeutics und verweist auf IPF-Potenzial | ||
ROYALTY PHARMA | 31,130 | +0,35 % | Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target | ||
BRIDGEBIO PHARMA | 45,400 | +1,89 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today... ► Artikel lesen | |
CORBUS PHARMACEUTICALS | 11,000 | -5,17 % | Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data | ||
SOLIGENIX | 1,375 | +7,42 % | Soligenix stärkt europäischen Beirat für Phase-3-Studie zu Lymphom-Medikament | ||
KALA BIO | 1,270 | -2,31 % | KALA BIO, Inc.: KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint | -- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related... ► Artikel lesen | |
ACLARIS THERAPEUTICS | 1,557 | -1,02 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025 | ||
NEUROGENE | 19,610 | +2,78 % | Neurogene stock price target maintained at $45 by H.C. Wainwright | ||
VYNE THERAPEUTICS | 0,372 | +15,23 % | VYNE Therapeutics Inc.: VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo | Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from... ► Artikel lesen |